<DOC>
	<DOCNO>NCT00571753</DOCNO>
	<brief_summary>The study conduct compare safety efficacy isoniazid administer adjust dose base NAT2 ( arylamine N-acetyltransferase type 2 ) genotype standard dose . The hypothesis genotype-adjusted dose superior standard dose regard hepatotoxicity early treatment failure , respectively , group slow rapid acetylators NAT2 .</brief_summary>
	<brief_title>Isoniazid Dose Adjustment According NAT2 Genotype ( IDANAT2 )</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<criteria>Patient inform give ample time opportunity think her/his participation give her/his write informed consent Patient willing able comply trial requirement , inclusive genotyping procedure Patient 18 75 year age ( inclusive ) whole trial , male female Patient newly diagnose pulmonary tuberculosis daily antituberculosis therapy indicate Patient smearpositive sputum Patient radiological evidence pulmonary infiltrate . Patients known contraindication isoniazid : acute hepatitis , macroscopic hematuria , allergy isoniazid , peripheral neuritis , coagulopathy , severe haemorrhagic diathesis , seizure disorder , psychosis Patients advance unstable chronic liver disease confirm result biochemical serological test eligibility assessment ( relevant abnormality follow liver test : ALT , AST , AP , total conjugate bilirubin ; positive serology hepatitis ) , assessed riskbenefit ratio participation study unfavourable ( inclusion upon decision clinical investigator ) Patients severe , lifethreatening disease life expectancy le 2 year Patients know AIDS ( CD4+ count &lt; 200/ml ) HIVseropositive patient receive HAART ( highly active antiretroviral therapy ) . Note : HIVpositive patient may include Patients diabetes mellitus Patients renal insufficiency ( creatinine clearance &lt; 30mL / min / 1.73m2 ) patient hemodialysis Patients clinical condition suggest he/she include ( decision clinical investigator ) Patients chronic infection require concomitant systemic antibacterial agent also active M. tuberculosis ( i.e . fluoroquinolones , aminoglycosides , macrolides ) Patients intake systemic antibacterial agent also active M. tuberculosis ( i.e . fluoroquinolones , aminoglycosides , macrolides ) within 4 week prior antituberculosis treatment Patients ever receive antituberculosis chemotherapy Patients take hepatotoxic agent regular basis take within 3 month study onset Patients known drug / continuous severe alcohol abuse ( drink 60 g alcohol daily ) Patients participate interventional clinical study ; Female patient pregnant lactating ; Female patient willing capable use two different contraceptive method throughout study , e.g . double barrier method ( e.g . diaphragm condom partner , intrauterine devise condom , sponge condom , spermicide condom ) . Acceptable alternative effective contraception also sexual abstinence vasectomize partner . In contrast , oral contraceptive recommend , since effectiveness may reduce due possible interaction rifampicin Patients place closed institution result court authority ' decision Patients know suspected comply study directives and/or know suspect reliable trustworthy Patients know suspected capable understand evaluate information give part formal information policy ( informed consent ) , particular regard foreseeable risk expose . Patients following include evaluation efficacy : Infection Mycobacterium avium complex Resistance M. tuberculosis isoniazid first screen test ( initial culture ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>pulmonary tuberculosis</keyword>
	<keyword>NAT2 genotyping</keyword>
	<keyword>hepatotoxicity isoniazid</keyword>
</DOC>